Introduction
Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis and is implicated in the development of a variety of human malignancies, including Hodgkin's lymphoma, Burkitt's lymphoma, nasopharyngeal carcinoma, and various lymphoproliferative disorders arising in immunocompromised individuals (Longnecker, 1998; Thorley-Lawson, 2001; Young and Murray, 2003) . EBV establishes a lifelong latent infection in B lymphocytes and independent studies report limited gene expression in B cells from healthy individuals harboring a latent EBV infection (Qu and Rowe, 1992; Chen et al., 1995; Babcock et al., 1998) . Viral latent membrane protein 2A (LMP2A) mRNA is frequently detected in peripheral blood B lymphocytes from healthy individuals and the protein is often present tumor biopsies from EBV-associated malignancies (Brooks et al., 1992; Tierney et al., 1994; Chen et al., 1995; Niedobitek et al., 1997; ThorleyLawson, 2001 ), suggesting that LMP2A plays an important role not only in viral latency, but also in the development of EBV-related diseases.
LMP2A is a transmembrane protein that functions to inhibit normal B-cell signal transduction by mimicking an activated B-cell receptor (BCR) (Miller et al., 1995; Portis et al., 2002) . The amino-terminal domain of LMP2A is tyrosine phosphorylated and constitutively associates with Src family protein tyrosine kinases (PTKs) as well as Syk, both important mediators of BCR signal transduction. Association of LMP2A with these tyrosine kinases is essential for the LMP2A-mediated block in BCR signaling (Burkhardt et al., 1992; Fruehling and Longnecker, 1997; Fruehling et al., 1998) . In addition, LMP2A activates the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which normally provides a survival signal in response to BCR signaling (Scholle et al., 2000; Swart et al., 2000; Fukuda and Longnecker, 2004) . Therefore, it is likely that LMP2A maintains viral latency by preventing normal BCR activation, which would initiate viral replication, while sustaining survival pathways in latently infected B cells.
The ability of LMP2A to provide survival signals to B cells has been demonstrated in vivo, where expression of an LMP2A transgene in mice interferes with normal Bcell development, allowing BCR-negative cells to exit the bone marrow and survive in peripheral lymphoid organs (Caldwell et al., 1998) . Bone marrow B cells from the LMP2A transgenic E (TgE) line undergo immunoglobulin (Ig) light-chain, but not heavy-chain gene rearrangement, indicating that LMP2A signaling bypasses the requirement for Ig recombination and allows IgM-negative cells, which would normally undergo apoptosis, to survive and colonize peripheral lymphoid organs (Caldwell et al., 1998) . Furthermore, bone marrow cells from LMP2A TgE transgenics in both wild-type and recombinase-activating gene (RAG)-deficient backgrounds form colonies in IL-7-containing methylcellulose, indicating that LMP2A bypasses the requirement for Ig rearrangement and allows for IL-7-driven B-cell proliferation (Caldwell et al., 1998; Caldwell et al., 2000) . The LMP2A-mediated effects on B-cell development and survival in vivo have been shown to require the signaling components Syk, BLNK (SLP-65) and Bruton's tyrosine kinase (Btk) (Merchant et al., 2000; Engels et al., 2001; Merchant and Longnecker, 2001 ). Recent studies involving DNA microarray technology demonstrate that expresssion of LMP2A in murine B cells induces abnormalities in gene expression similar to those found in malignant cells of Hodgkin's lymphoma, particularly genes involved in cell cycle induction, apoptosis inhibition, and suppression of cell-mediated immunity . The ability of LMP2A to mediate Bcell survival and to induce global transcriptional alterations in vivo implicates LMP2A in the development of EBV-associated malignancies such as Hodgkin's lymphoma.
A central mediator of B-cell survival during development is Ras, a small GTP-binding protein which is the common upstream molecule of several signaling pathways, including Raf/mitogen-activated protein kinase/ ERK kinase (MEK)/extracellular-signal-related kinase (ERK) and PI3K/Akt (Steelman et al., 2004) . During Bcell development, productive Ig V H gene rearrangement is necessary for formation of the pre-BCR complex, which then allows for survival of pre-B cells (FuentesPanana et al., 2004; Milne et al., 2004) . Failure to express a functional pre-BCR complex leads to cell death by apoptosis. Inhibition of apoptosis during B-cell development has been linked to Ras activation of PI3K and NF-kB pathways, which stimulate the induction of at least two antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-xL (Merino et al., 1994; Grillot et al., 1996; Downward, 1998) . Knockout mice unable to express Syk, BLNK, Ras, or PI3K exhibit an arrest early in Bcell development, indicating their importance for survival of B-cell progenitors (Turner et al., 1995; Fruman et al., 1999; Pappu et al., 1999; Nagaoka et al., 2000) . Bcl-2 expression is normally induced at the pro-B stage, is then downregulated in pre-B cells, and later upregulated in mature B cells where it is essential for the maintenance of peripheral B cells (Merino et al., 1994) . In contrast, Bcl-xL is normally expressed at high levels in pre-B cells and is downregulated in mature B cells; however, Bcl-xL is rapidly induced in peripheral B cells upon BCR activation (Grillot et al., 1996) . Only one of the two Bcl-2 family members is upregulated at each survival checkpoint, indicating that tight regulation of these antiapoptotic proteins is critical for maintaining proper B-cell selection during lymphoid development.
The presence of BCR-negative B lymphocytes in the spleens of LMP2A TgE transgenic mice resembles a transgenic mouse model described by Shaw et al. (1999b) , in which B-lineage-directed expression of activated Ras was examined in the context of an RAG1-deficient background. In these mice, B cells unable to properly rearrange Ig genes were able to survive and persist in the periphery, similar to LMP2A TgE transgenic mice. In addition, expression of activated Ras in cells competent for Ig light chain, but not heavy chain, gene rearrangement induced the progression of B cells beyond this critical developmental checkpoint (Shaw et al., 1999a) . The similarities between the activated Ras and LMP2A TgE mouse models led us to hypothesize that LMP2A utilizes Ras activation to mediate B-cell survival in vivo. In this study, we have demonstrated that B cells from LMP2A TgE transgenic mice contain increased levels of activated Ras and high expression of Bcl-xL. B cells from LMP2A TgE transgenic mice were sensitive to apoptosis induction in the presence of specific inhibitors of Ras, PI3K, and Akt, but not Raf or MEK, indicating that LMP2A preferentially activates the Ras/PI3K/Akt pathway to mediate B-cell survival. Increased B-cell apoptosis correlated with reduced expression of Bcl-xL, suggesting that this Bcl-2 family member may be involved in apoptosis inhibition mediated by LMP2A. These findings provide new insight regarding specific cellular pathways utilized by LMP2A to maintain cell survival, and possibly contribute to oncogenesis, in B lymphocytes latently infected with EBV.
Results

LMP2A requires Ras signaling for early B-cell progenitor survival
Both LMP2A and activated Ras can drive B-cell development and survival in the absence of Ig heavychain rearrangement; therefore, it was hypothesized that LMP2A mediates survival of BCR-negative B cells in vivo through activation of the Ras pathway. In order to determine whether the absence of Ras signaling impairs the ability of LMP2A to mediate B-cell survival, LMP2A TgE mice were bred with mice expressing a dominant-negative form of Ras (H-rasN17) under the lck promoter and Ig Em enhancer, directing expression to the earliest committed B lymphocyte progenitors (Iritani et al., 1997) . H-rasN17 mice demonstrate arrested B-cell development at a very early stage and before the formation of the pre-BCR, similar to mice defective for IL-7 receptor signaling (Grabstein et al., 1993) .
Bone marrow and splenic cells from LMP2A TgE and H-rasN17 mice were analysed by flow cytometry to compare B-cell numbers. As reported previously (Iritani et al., 1997) and shown in Figure 1 , the percentage of B cells was significantly reduced in the bone marrow and moderately reduced in the spleens of H-rasN17 mice when compared to nontransgenic mice. These data are consistent with a defect in survival at a very early stage of B-cell development (Iritani et al., 1997) . LMP2A TgE mice are characterized by the absence of IgM-positive B cells in the bone marrow (Caldwell et al., 1998) . Although IgM-negative, CD19-positive B cells were present in the bone marrow of LMP2A TgE X HrasN17 mice, the percentage of these cells was dramatically reduced, indicating that B-cell survival is blocked LMP2A-mediated activation of the Ras/PI3K/Akt pathway T Portis and R Longnecker in the presence of the H-rasN17 transgene ( Figure 1a ). As shown in Figure 1b , the percentage of B cells in the spleens of LMP2A TgE X H-rasN17 mice was slightly reduced when compared to TgE mice; however, the difference was not stastically significant. These data indicate that, similar to results observed by Iritani et al. (1997) , a small percentage of B cells can escape the block in B-cell development induced by the H-rasN17 transgene and colonize peripheral lymphoid organs such as the spleen. Ras is believed to be involved in IL-7 receptor signaling, one of the earliest and most critical events in B-cell development (Milne et al., 2004) . Therefore, it is likely that LMP2A cannot mediate B-cell survival when there is a defect in Ras signaling at the earliest stages of B-cell development, prior to the formation of precursor B cells. The dependence of LMP2A on IL-7 and Ras signaling was more accurately assessed in vitro by measuring B lymphoid precursor cell survival in methylcellulose cultures. Bone marrow cells were placed in methylcellulose cultures containing IL-7 for 7-10 days in order to determine whether LMP2A can bypass the requirement for Ras for B-cell survival at the earliest stages of development. Colonies that form in these cultures require IL-7 for growth and are 495% CD19 þ . Compared to bone marrow B cells from non-transgenic mice, cells from LMP2A TgE transgenic mice tend to form larger colonies in methylcellulose, indicating increased survival and proliferation of precursor B cells ( Figure 2 ). As expected, no colonies formed in bone marrow cultures from H-rasN17 mice due to the absence of Ras and IL-7 receptor signaling. Similarly, no colonies formed in bone marrow cultures from LMP2A TgE X H-rasN17 mice, indicating that LMP2A cannot bypass the requirement for Ras and IL-7 signaling to mediate survival of precursor B cells. Owing to the limitations of the H-rasN17 mouse model, in which few B cells are formed, in vitro experiments were designed to further characterize the dependence of LMP2A on Ras signaling in B cells. LMP2A-mediated activation of the Ras/PI3K/Akt pathway T Portis and R Longnecker activated Ras than nontransgenic mice. Furthermore, activated Ras expression in B cells from LMP2A TgE mice correlated with significantly increased levels of the downstream antiapoptotic Bcl-2 family member protein Bcl-xL. These results are in agreement with our previous observation of elevated Bcl-xL mRNA expression (2-4-fold) in splenic B cells from LMP2A TgE mice . In mature, resting B cells, Bcl-xL expression is induced only after BCR activation, CD40 ligation, or lipopolysaccharide (LPS) stimulation. Instead, Bcl-2 is constitutively expressed, presumably to maintain survival in the absence of B-cell activation (Grillot et al., 1996) . In addition to the unmodified 26 kDa form of Bcl-2 present in B cells from nontransgenic littermates, B cells from LMP2A TgE mice expressed a slower migrating, band-shifted form of Bcl-2 (Figure 3 ). Bcl-2 is post-translationally modified by serine and/or threonine phosphorylation, which has been shown to positively or negatively regulate Bcl-2 activity, depending upon the type and extent of phosphorylation (Haldar et al., 1995; Ito et al., 1997; Yamamoto et al., 1999; Ruvolo et al., 2001) . Recent studies have shown that multiple-site phosphorylation of Bcl-2 at Thr69, Ser70, and Ser87 by JNK results in the formation of a band-shifted form of Bcl-2 and inactivation of the protein (Yamamoto et al., 1999) . Therefore, the levels of activated, phosphorylated JNK were measured in LMP2A TgE splenic B cells. As shown in Figure 3 (lower panel), increased levels of phosphorylated JNK were present in LMP2A TgE B cells expressing the band-shifted form of Bcl-2, suggesting that JNK activation mediates Bcl-2 phosphorylation and inactivation in peripheral B cells from LMP2A TgE mice. Due to tight regulation of antiapoptotic proteins during B-cell maturation, Bcl-2 inactivation may be necessary in order to sustain abnormally elevated Bcl-xL expression in mature, resting B cells. Together, these data indicate that LMP2A activates the Ras pathway and Bcl-xL expression in peripheral, BCR-negative B cells. Furthermore, LMP2A likely maintains survival of these cells by disrupting the normal regulation of Bcl-xL and Bcl-2 expression patterns to favor prolonged survival in the absence of BCR signaling.
Ras inhibition induces apoptosis in LMP2A-expressing B cells
In order to determine whether activated Ras contributes to cell survival in LMP2A TgE mice, splenic B cells were treated with manumycin A, a farnesyl transferase Figure 2 B-cell colony formation in LMP2A TgE X H-rasN17 mice. Bone marrow cells from 4-week-old nontransgenic (NonTg), LMP2A TgE (TgE), H-rasN17, and LMP2A TgE X H-rasN17 mice were placed in methylcellulose cultures containing 10 ng/ml recombinant mouse IL-7 and colony formation was measured after 7-10 days. Colonies were routinely 495% CD19 þ . At least four mice from each background were compared and representative cultures for each genotype are shown Figure 3 Expression of activated Ras and Bcl-2 family member proteins in LMP2A TgE mice. Freshly isolated splenic B cells from 4 week old nontransgneic (NonTg) and LMP2A TgE (TgE) mice were purified on MACS columns using CD19-coated magnetic beads, lysed, and utilized for Western blot analysis. Activated Ras was measured by immunoprecipitation of cell lysates with a GST fusion protein corresponding to the human Ras binding domain of Raf-1, followed by Western blot hybridization with anti-mouse Ras antibodies. Standard Western blots were performed with antimouse antibodies specific for Bcl-xL, Bcl-2, GAPDH, JNK, and phosphorylated JNK (ppJNK) and representative blots from four independent experiments are shown LMP2A-mediated activation of the Ras/PI3K/Akt pathway T Portis and R Longnecker inhibitor of Ras post-translational modification. Ras activation requires translocation of the protein from the cytoplasm to the inner aspect of the plasma membrane and farnesylation is necessary for complete activation and membrane translocation of Ras (Adjei, 2001) . Apoptosis induction in splenic B cells was assessed after 18 h of manumycin A treatment by measuring dUTP incorporation, a late indicator of apoptosis. Since unstimulated, primary B cells are sensitive to spontaneous apoptosis during long term in vitro culturing, cells were treated with anti-CD40 antibody to enhance cell survival. When compared to DMSO control treatment, a significant increase in apoptosis was observed in B cells from both LMP2A TgE and nontransgenic mice after treatment with manumycin A (Figure 4a and b) . Additionally, B cells from LMP2A TgE mice appeared to be more sensitive to lower doses of manumycin A (5 mM) than cells from nontransgenic mice, suggesting that Ras activation by LMP2A is important for maintaining survival of these BCR-negative B cells. It is interesting to note that, while anti-CD40 treatment dramatically enhanced the survival of B cells from nontransgenic mice, this stimulus did not significantly influence the survival of LMP2A TgE B cells (Figure 4b) . Furthermore, enhanced cell survival mediated by anti-CD40 correlated with increased Bcl-xL expression in B cells from nontransgenic mice (compare Figures 3 and  4c ). Similar levels of apoptosis induction by manumycin A treatment were observed by annexin V staining at 5 h in the absence of CD40 antibody (data not shown). Increased apoptosis induction by manumycin A treatment correlated with decreased expression of activated Ras in a time-dependent manner, indicating the specificity of the inhibitor (Figure 4c ). In addition, increased apoptosis induction by manumycin A correlated with a time-and dose-dependent decrease in BclxL expression (Figure 4c and data not shown), suggesting that LMP2A mediates B-cell survival through Ras activation of Bcl-xL expression.
Inhibition of PI3K/Akt, but not Raf/MEK, induces apoptosis in LMP2A-expressing B cells
Ras family members demonstrate varying abilities to activate the Raf/MEK/ERK and PI3K/Akt cascades. Ki-Ras is primarily associated with activation of the Raf/MEK/ERK pathway, which is involved in the regulation of cellular proliferation and differentiation. In contrast, Ha-Ras preferably activates the PI3K/Akt pathway, which is associated with inhibition of apoptosis (Chang et al., 2003; Steelman et al., 2004) . In order to determine which downstream Ras pathway is activated by LMP2A, apoptosis of splenic B cells was measured after treatment with specific inhibitors of PI3K, Akt, Raf, and MEK. As shown in Figure 5a , splenic B cells treated with PI3K (Ly294002) and Akt inhibitors in the presence of anti-CD40 demonstrated a dose-dependent increase in apoptosis. Furthermore, B cells from LMP2A TgE mice were much more sensitive to apoptosis induction at the lower concentrations of both inhibitors (20 and 40 mM). B cells from LMP2A TgE and nontransgenic mice were equally sensitive to apoptosis induction in the presence of high concentrations of both inhibitors (80 mM, Figure 5a ). These experiments were repeated in the absence of anti-CD40 treatment to demonstrate that CD40-mediated PI3K/Akt activation is not interfering with apoptosis induction in this system (Figure 5b ). Similar to the results presented in Figure 5a Standard Western blots were performed after treatment with manumycin A for 3, 4, or 5 h in the presence of 1 mg/ml anti-mouse CD40 using anti-mouse antibodies for Ras, Bcl-xL, and GAPDH. Experiments were repeated a minimum of three times and representative blots are shown LMP2A-mediated activation of the Ras/PI3K/Akt pathway T Portis and R Longnecker apoptosis induction at the lower concentrations of PI3K and Akt inhibitors, indicating that LMP2A utilizes PI3K/Akt activation to mediate B-cell survival. In contrast to the results obtained using PI3K and Akt inhibitors, treatment of splenic B cells with increasing doses of an Raf inhibitor (ZM336372) did not induce apoptosis over the levels of control DMSOtreated cells (Figure 5c ). Treatment with an MEK inhibitor (U0126), however, induced a dose-dependent increase in apoptosis in B cells from nontransgenic mice, with the highest doses equal to that in unstimulated, DMSO-treated cells. Treatment of LMP2A TgE B cells with the highest doses of U0126 increased the levels of apoptosis slightly above those in unstimulated, DMSOtreated cells; however, the difference was not statistically significant ( Figure 5c ). As U0126 has been reported to interfere with immunofluorescence analysis of apoptosis (Blank et al., 2002) , these experiments were repeated using the PD98059 MEK inhibitor. As shown in Figure 5c , treatment with PD98059 did not induce apoptosis over the levels of control DMSO-treated cells. These data indicate that LMP2A mediates B-cell survival through the PI3K/Akt cascade and not through activation of the Raf/MEK/ERK pathway.
In addition to apoptosis induction, the expression levels of Bcl-xL were measured after 5 h of treatment with each inhibitor in order to determine which Ras pathways regulate Bcl-xL expression in LMP2A TgE B cells and whether Bcl-xL expression correlates with apoptosis induction. Not surprisingly, expression of BclxL was reduced in a dose-dependent manner in B cells from both LMP2A TgE and nontransgenic mice after treatment with PI3K and Akt inhibitors, while treatment with Raf and MEK inhibitors did not significantly affect Bcl-xL expression ( Figure 6 ). These results, taken (Scholle et al., 2000; Fukuda and Longnecker, 2004) . Here, we extend these findings to show that LMP2A activates this pathway to mediate survival in primary B cells in vivo. Furthermore, we demonstrate that LMP2A-mediated B-cell survival occurs through constitutive Ras activation and is due at least in part to Bcl-xL upregulation. Interestingly, the major isoform of the Kaposi's sarcoma-associated herpesvirus (KSHV) K15 protein was recently shown to activate the Ras/ mitogen-activated protein kinase (MAPK) and NF-kB pathways, which required Src family tyrosine phosphorylation of a YEEVL motif similar to the YEEA motif contained in LMP2A (Brinkmann et al., 2003) . The ability of LMP2A to activate Ras, a proto-oncogene that is amplified or mutated in a large percentage of cancers, suggests that this viral latency protein plays a more active role in the development of human malignancies than previously thought.
Our initial experiments demonstrating reduced B-cell development and survival in TgE X H-rasN17 doubly transgenic mice are both compelling and supportive; however, it is difficult to conclude that Ras is absolutely necessary for LMP2A-mediated B-cell survival based on this system alone since B-cell development is arrrested at such an early stage. We cannot rule out the possibility that expression of the H-rasN17 transgene occurs prior to LMP2A expression in the doubly transgenic mice, thereby creating a more dominant phenotype; however, both constructs are driven by the Ig Em heavy-chain enhancer and therefore should theoretically be expressed at the same point during B-cell development. The complete absence of B-cell colonies in methylcellulose indicates that LMP2A cannot bypass Ras and IL-7 signaling and allow for the survival and/or proliferation of more premature lymphoid progenitor cells. The extent of this requirement and the precise developmental stages at which Ras signaling is necessary for LMP2A function, however, cannot be accurately inferred from these studies. Instead, we have utilized an in vitro model to examine the requirement for Ras in LMP2A-mediated survival of peripheral, splenic B cells.
Ras family members are common upstream molecules of several signaling pathways, including Raf/MEK/ ERK and PI3K/Akt. The Ki-Ras family member has been associated with Raf/MEK/ERK activation, while Ha-Ras is associated with PI3K/Akt activation (Chang et al., 2003; Steelman et al., 2004) . We have found that LMP2A utilizes the PI3K/Akt pathway to mediate survival of B cells, which suggests that Ha-Ras is the Ras family member that is activated by LMP2A. It is possible that that both pathways can be activated by LMP2A; however, the PI3K/Akt pathway is associated with inhibition of apoptosis and Raf/MEK/ERK is associated with cellular proliferation, which was not measured in these experiments. Importantly, both pathways can activate NF-kB, which is a key regulator of Bcl-xL expression (Steelman et al., 2004) .
We propose that, during B-cell development in our transgenic mouse model, LMP2A mimics an activated pre-BCR through constitutive activation of Ras, PI3K, Akt, and Bcl-xL expression, which allows BCR-negative cells to bypass developmental checkpoints and survive in peripheral lymphoid organs. This type of activity by LMP2A may also be involved in the development of Hodgkin's lymphoma, in which the malignant Hodgkin/ Reed-Sternberg cells have lost Ig expression but are still able to survive (Kuppers et al., 2002) . In support of this, Bcl-xL is overexpressed in a variety of EBV-associated cancers, including Hodgkin's lymphoma, non-Hodgkin's lymphoma, and human immunodeficiency virus (HIV)-associated lymphomas, and high Bcl-xL expression has been associated with advanced disease and poor prognosis (Schlaifer et al., 1995; Schlaifer et al., 1996; Bairey et al., 1999) .
Upon BCR activation, there is a rapid induction of PI3K, which results in the recruitment and activation of Akt. Deletion of PTEN, a negative regulator of Akt, or overexpression of active Ras, PI3K, or Akt renders cells resistant to apoptosis (Cantley and Neel, 1999; Tang et al., 2000) . Akt phosphorylates of a wide variety of targets involved in apoptosis regulation, including Bad, a proapoptotic member of the Bcl-2 family, caspase-9, MDM2, and GSK-3. In addition, Akt inhibits the expression of proapoptotic genes by phosphorylating members of the forkhead family of transcription factors and activates transcription of antiapoptotic genes by phosphorylating IkB kinase a (IKKa), which positively regulates NF-kB activity (Sheid and Woodgett, 2001) . Bcl-xL is one such antiapoptotic gene whose expression is regulated by NF-kB; therefore, we speculate that increased levels of Bcl-xL in B cells from LMP2A TgE mice are due to Akt-mediated NF-kB activation. We cannot, however, rule out the possibility that activation of other antiapoptotic factors by Akt may contribute to survival in LMP2A TgE B cells. For instance, phosphorylation of proapoptotic Bad by Akt may inhibit its ability to mediate apoptosis via heterodimerization with Bcl-xL or Bcl-2 in LMP2A-expressing cells. However, the dramatic increase in overall Bcl-xL levels and the presence of phosphorylated, presumably inactivated, Bcl-2 in resting B cells from LMP2A TgE mice does not indicate that heterodimerization of Bcl-2 family members plays a significant role in LMP2A-mediated survival in this system.
The observation of increased levels of Bcl-xL expression in resting, peripheral B cells from LMP2A TgE mice indicates that this protein is abnormally regulated by LMP2A. These data are supported by previous observations of elevated Bcl-xL mRNA expression in resting splenic B cells from LMP2A TgE mice . Bcl-xL is normally expressed at high levels in pre-B cells and is downregulated in mature B cells; however, Bcl-xL is rapidly induced in peripheral B cells upon BCR activation (Grillot et al., 1996) . Bcl-xL is also expressed in proliferating B cells in germinal centers, suggesting that Bcl-xL plays a role in the survival and maintenance of pre-B cells and activated mature B cells (Krajewski et al., 1994) . Constitutive expression of BclxL in vivo promotes the accumulation of B-cell precursers and mature B cells that contain nonproductive rearrangements of Ig genes (Fang et al., 1996) . It has been proposed that Bcl-xL functions to maintain cell survival during the rearrangement of Ig heavy-chain alleles. Cells with functional heavy-chain gene rearrangements and formation of a pre-BCR then further upregulate Bcl-xL expression and become competent for light-chain rearrangement (Fang et al., 1996) . It is at this stage that LMP2A may be keeping Bcl-xL expression elevated by mimicking pre-BCR signals.
At the mature B-cell stage, induction of Bcl-2 appears to represent a developmental switch involved in the selection and maintenance of peripheral B cells. In our model, Bcl-xL is overexpressed in peripheral, splenic B cells and this correlates with the appearance of a slower migrating, band-shifted form of Bcl-2 which has previously been observed only in cells treated with antimitotic, chemotherapeutic agents (Yamamoto et al., 1999; Ruvolo et al., 2001) . Bcl-2 is phosphorylated in response to many stimuli and reports vary as to whether this modification activates or inactivates the molecule. To date, however, only inhibition of Bcl-2 function has been associated with the formation of a stable, bandshifted form of Bcl-2 on denaturing gel electrophoresis. This multiple-site, serine/threonine phosphorylation of Bcl-2 was shown to be mediated by the JNK pathway (Yamamoto et al., 1999) . In LMP2A TgE splenic B cells, increased levels of phosphorylated JNK correlated with increased expression of the band-shifted form of Bcl-2, suggesting that JNK phosphorylation inactivates Bcl-2 in these cells. Indeed, JNK activation may be a direct target of LMP2A as others have shown increased JNK phosphorylation in LMP2A-expressing epithelial cell lines (Chen et al., 2002) . Based on the observation of abnormally elevated levels of BclxL in splenic B cells from LMP2A TgE mice, it is possible that LMP2A prevents the normal developmental switch from Bcl-xL to Bcl-2 induction in B cells through constitutive phosphorylation and inhibition of Bcl-2 activity.
In summary, we have demonstrated that LMP2A mediates the survival of primary, BCR-negative B cells by constitutive activation of the Ras/PI3K/Akt pathway. Furthermore, activated Ras expression in LMP2A-expressing B cells correlated with elevated levels of BclxL and a slower migrating, band-shifted form of Bcl-2. B-cell apoptosis induced by Ras, PI3K, and Akt inhibitors correlated with reduced expression of BclxL, suggesting that this Bcl-2 family member may be involved in apoptosis inhibition mediated by LMP2A. These findings provide insight into the molecular mechanisms utilized by LMP2A to maintain viral latency, which may inadvertantly contribute to the development of EBV-associated malignancies.
Materials and methods
Isolation of primary B cells from mice
Construction and characterization of the Em TgE LMP2A transgenic mice have been described previously (Caldwell et al., 1998) . Transgenic mice expressing a dominant-negative form of Ras (H-rasN17) under the lck promoter and Ig heavy-chain enhancer (Em) were a generous gift from Dr Roger Perlmutter (Iritani et al., 1997) . All animals were housed at the Northwestern University Center for Experimental Animal Resources in accordance with university animal welfare guidelines. To isolate bone marrow B cells, femurs and tibias were flushed with 1 Â phosphate-buffered saline (PBS) containing 1% penicillin/streptomycin. Red blood cells were lysed in 155 mM ammonium chloride and cells were either used directly for flow cytometric analysis or placed in 3 ml Methocult M3630 methylcellulose cultures containing 10 ng/ml recombinant mouse IL-7 (Stemcell Technologies, Vancouver, British Colombia). Colony formation was observed after 7-10 days. Spleens were dissociated between frosted slides in RPMI to prepare single cell suspensions. Red blood cells were lysed and CD19 þ B cells from transgenic mice were measured by flow cytometric analysis.
Apoptosis detection
Splenic cells isolated from LMP2A TgE and nontransgenic mice were placed in RPMI containing 10% fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/streptomycin, and 10 mM 2-mercaptoethanol with or without the addition of 1 mg/mL anti-mouse CD40 (BD Pharmingen, San Diego, CA, USA). Cells were then treated with either dimethyl sulfoxide (DMSO) alone or varying concentrations of inhibitors dissolved in DMSO. Inhibitors included manumycin A (Calbiochem, San Diego, CA, USA), Ly294002 (Cell Signaling Technology, Beverly, MA, USA), Akt inhibitor (Calbiochem), ZM336372 (Calbiochem), U0126 (Cell Signaling Technology), and PD98059 (Calbiochem). Apoptosis induction was measured after 5 h of inhibitor treatment by labeling cells with Annexin V-FITC (Clontech, Palo Alto, CA, USA). Cells were simultaneously stained with CD19-PE antibodies to detect B cells undergoing apoptosis. Apoptosis was also measured after 18 h of inhibitor treatment using the APO-DIRECT kit for labeling DNA breaks with dUTP-FITC (BD Biosciences, San Diego, CA, USA). For these experiments, B cells were first purified at 41C on magnetic cell sorting (MACS) columns utilizing magnetic beads coated with CD19 antibodies (Miltenyi Biotec, Auburn, CA, USA).
Protein isolation and Western blots
Splenic B cells were lysed in buffer containing 125 mM HEPES, pH 7.5, 750 mM NaCl, 50 mM MgCl 2 , 5 mM EDTA, 10% glycerol, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 25 mM NaF, and 1 mM sodium orthovanadate, and protein levels were quantitated in standard Bradford assays (BioRad, Hercules, CA, USA). Equivalent amounts of protein were subjected to heat denaturation at 701C for 10 min. Samples were run on 10% SDS-PAGE gels (BioRad, Hercules, CA, USA) and transferred to Immobilon-P membranes (Millipore, Bedford, MA, USA). Activated Ras was measured by immunoprecipitation of cell lysates with a GST fusion protein corresponding to the human Ras binding domain of Raf-1, followed by Western blot hybridization with anti-mouse Ras antibodies (1 mg/ml, Upstate, Charlottesville, VA, USA) in TBST (150 mM NaCl, 50 mM Tris-Cl, pH 8, and 0.05% Tween 20) containing 2% BSA. Anti-mouse antibodies specific for Bcl-xL and Bcl-2 (BD Biosciences, San Diego, CA, USA) were diluted 1 : 1000 in TBST containing 2% BSA and used for Western blotting. Anti-mouse antibodies specific for stress-activated protein kinase (SAPK)/Jun N-terminal protein kinase (JNK) and Phospho-SAPK/JNK (Cell Signaling Technology, Beverly, MA, USA) were diluted 1 : 1000 in TBST containing 2%
BSA. Anti-mouse antibodies to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Abcam, Cambridge, MA, USA) were diluted 1 : 10000 in TBST containing 2% BSA. All proteins were detected using the appropriate secondary antibodies conjugated to horseradish peroxidase at 1 : 2000 in TBST, followed by ECL detection (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and film exposure.
